Impact of the New Zealand pine bark extract (Enzogenol®) on sucrose metabolism and glycaemic responses in healthy adults – a single-blind, randomised, placebo-controlled, crossover trial
- Conditions
- DysglycaemiaDiabetesGlycaemic controlDiet and Nutrition - Other diet and nutrition disordersMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12624000491561
- Lead Sponsor
- Riddet Institute, Massey University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 40
The inclusion criteria will be:
• Healthy participants (males and females)
• Aged between 18-60 years old
• Body Mass Index (BMI) of 18.5-29.9kg/m2 (Healthy and overweight)
• Glycated haemoglobin A1c (HbA1c) <39 mmol/mol (ADA guidelines)
• Fasting blood glucose (FBG) <5.6 mmol/L (ADA guidelines)
• Able to communicate well in English
The exclusion criteria will be:
• Body Mass Index (BMI) >29.9kg/m2 (obese)
• Glycated haemoglobin A1c (HbA1c) >39 mmol/mol (ADA guidelines)
• Fasting blood glucose (FBG) >5.6 mmol/L (ADA guidelines)
• Known food allergies or intolerance to pine bark extract or mulberry leaf extract
• Having dietary restrictions or dietary disorders
• Pre-existing medical conditions (cardiovascular disease, hypertension, diabetes etc.) or taking medications including anti-hyperglycaemic drugs and insulin known to affect glucose metabolism or regulation
• Use of steroids, protease inhibitors or antipsychotics medicines known to influence glucose metabolism and body fat distribution
• Pregnant or breastfeeding
• Smoking
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method